---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-109439"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2024-10-17T23:59:59+00:00"
generated_at: "2026-05-30T13:17:57.174273+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Verastem reports 31% ORR with avutometinib/defactinib in RAMP 201; NDA submission ongoing

## Summary
- Confirmed ORR of 31% overall (44% KRAS mutant, 17% KRAS wild type) by BICR.
- Median duration of response 31.1 months; median PFS 12.9 months overall.
- Discontinuation rate due to AEs was 10%; safety manageable with dose modifications.
- Low-dose regimen (1.6 mg avutometinib) suboptimal; 22% progressed within 4 months vs 12% at 3.2 mg.
- Rolling NDA submission to FDA for avutometinib+defactinib in recurrent LGSOC is underway.

## SEC filing metadata
- accession: 0001104659-24-109439
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2024-10-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465924109439/0001104659-24-109439-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465924109439/tm2426322d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-109439
- JSON: https://secwatch.observer/filing/0001104659-24-109439.json
- Plain text: https://secwatch.observer/filing/0001104659-24-109439.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.